Here's Why You Should Add ResMed (RMD) To Your Portfolio
Zacks Investment Research | Oct 29, 2019 04:26AM ET
ResMed Inc. (NYSE:RMD) has been gaining investors’ confidence on consistently positive results. Over the past year, the company’s shares have outperformed its industry . The stock has gained 38.3% during the same time compared with 6.4% growth of the industry. Also, the company has outperformed the S&P 500’s 12.7% rise during this period.
The renowned cloud-connected medical devices and out-of-hospital software-as-a-service (“SaaS”) business provider, which specializes in sleep apnea devices, has a market cap of $20.91 billion. The company’s five-year projected growth rate looks impressive at 10.6%. It is expected to scale new highs in the near term. The company has average positive earnings surprise of 5.3% for the trailing four quarters.
With solid prospects, the Zacks Rank #2 (Buy) company is a worthy investment choice right now.
What Makes the Stock an Attractive Pick?
Product Launches: ResMed successfully launched its portable oxygen concentrator (Mobi) in the United States for Chronic Obstructive Pulmonary Disease (“COPD”) or other chronic diseases. Following this, it is planning a complete launch in other countries in 2019, after acquiring the necessary clearances. The company also launched an automated ReSupply solution for all U.S. home medical equipment (“HME”) providers in the United States.
Further, it recently expanded the AirFit mask portfolio by introducing AirFit N30i (a nasal CPAP mask) in the United States. For 2019, the company has more launches planned for other geographies. The company’s three most recent mask launches, namely, F30, N30i and P30i, have been contributing to the top line significantly. In October 2019, it launched N30 (a tube-down nasal cradle CPAP mask), which is its latest offering.
Acquisitions and Partnerships to Add Value: ResMed recently formed an alliance with Cerner Corporation (NASDAQ:CERN) within ResMed’s SaaS portfolio to help care providers take more informed treatment decisions, thereby reducing costs and delivering hassle-free healthcare.
In March, ResMed acquired home medical equipment provider HB Healthcare in South Korea. ResMed intends to reach millions of patients through HB Healthcare’s wide network of distributor partners.
The company also acquired Propeller Health (a digital therapeutics company, providing connected health solutions for COPD and asthma patients) in January 2019. Per ResMed, this is a significant value-addition to its respiratory care portfolio.
Get The News You Want
Further, ResMed is working toward the collaboration with Verily to develop software solutions that will assist healthcare providers to discover, diagnose, treat and manage individuals with sleep apnea and other breathing-related sleep conditions.
End-Market Growth Strong: The company is expecting strong growth for the atrial fibrillation and chronic disease management segments. It has been witnessing robust growth in its Brightree service portfolio and additional contribution from MatrixCare and HEALTHCAREfirst buyouts. It is also concentrating on the development of homecare ventilation for COPD, Amyotrophic Lateral Sclerosis (“ALS”) and other respiratory disorders for the emerging markets in China, India and Brazil.
Which Way Are Estimates Heading?
The estimate revision trend for the company for the current year is impressive. Over the past 30 days, the Zacks Consensus Estimate for its earnings has moved up 2.6% to $4.02.
The Zacks Consensus Estimate for 2020 revenues is pegged at $2.86 billion, suggesting 9.9% rise from the year-ago reported number.
Other Key Picks
Some other top-ranked stocks from the broader medical space are Aphria Inc. (TSX:APHA) , Owens & Minor, Inc. (NYSE:OMI) and LeMaitre Vascular, Inc. (NASDAQ:LMAT) .
Aphria, currently carrying a Zacks Rank #2, has projected first-quarter 2020 earnings growth rate at 113.33%. You can see Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.